Hiten D. Patel, MD, MPH

Hiten D. Patel, MD, MPH, completed residency training in urologic surgery at the James Buchanan Brady Urological Institute and is currently a clinical instructor and fellow in urologic oncology at Loyola University Medical Center. He has published studies related to epidemiology, comparative effectiveness, evidence-based reviews, and clinical trials in urologic oncology and related fields.

Articles by Hiten D. Patel, MD, MPH

Hiten D. Patel, MD, MPHJournal | December 14, 2021
These results formed the basis for the FDA’s approval of enzalutamide for the treatment of patients with mHSPC.
Read More
Hiten D. Patel, MD, MPHJournal | December 14, 2021
Dr. Michael S Hofman reported findings from the phase 2 TheraP (ANZUP 1603) clinical trial.
Hiten D. Patel, MD, MPHJournal | December 14, 2021
Dr. Sumanta K. Pal et al, reported the results of the study comparing three MET inhibitors with sunitinib in pRCC.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | March 26, 2021
Efortumab vedotin prolonged OS in patients who had previously received chemotherapy and checkpoint inhibitors.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | March 10, 2023
The phase 3 CLEAR trial showed improved OS for lenvatinib plus pembrolizumab as first-line therapy for advanced RCC.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | March 26, 2021
Nivolumab improves disease-free survival, non-urothelial tract recurrence-free survival, and metastasis-free survival.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | August 23, 2023
The phase 2 SWOG 1500 trial showed improvement in progression-free survival for cabozantinib in metastatic papillary RCC.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | May 7, 2023
Relugolix represents a new oral option for GnRH receptor antagonism.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | December 2, 2022
Establishing Cabazitaxel as third-line therapy for metastatic castration-resistant prostate cancer by the phase 4 CARD trial.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | February 22, 2021
177Lu-PSMA-617 was able to generate more PSA responses of at least 50% reduction compared to taxane cabazitaxel in mCRPC.
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | October 12, 2023
Adding enzalutamide to androgen deprivation therapy improved progression-free survival in hormone-sensitive prostate cancer.